Removing Neumann is a difficult decision for Son, who has long believed in WeWork and Neumann's vision to quickly expand the company.Technologyread more
The Kingdom and oil and gas industry have been slow to shore up defenses, raising red flags about the possibility of longer term fall-out in the region.Technologyread more
Datadog went public on Thursday and instantly hit a $10 billion valuation, becoming the fourth cloud software debut to reach that level this year.Technologyread more
There are challenges with Iran, North Korea, the Afghan Taliban, Israel and the Palestinians — not to mention a number of trade pacts.Politicsread more
Blackstone Executive Vice Chairman Tony James says he's less optimistic now than before that the U.S.-China trade war could be resolved, but even a smaller deal could help...World Economyread more
In his new memoir, "The Ride of a Lifetime," Iger explains why he decided against the deal to buy Twitter.Technologyread more
In perhaps Buffett's first televised profile, he explained a method of investing that prioritizes bargains and makes use of an occasional baseball analogy.Marketsread more
The massive market transformation this month that some on Wall Street called a "once in a decade opportunity" might have just been a one-off technical move because of taxes.Marketsread more
A 58% majority of registered voters express unease about voting for Trump, but slightly more say the same about Joe Biden and Bernie Sanders, while Elizabeth Warren fares only...Politicsread more
A temporary airspace closure forced flights coming into Dubai from Australia, Singapore and India to be diverted to nearby airports.Airlinesread more
Schiff had previously shied away from calling for impeachment, but his comments on CNN's "State of the Union" indicate his stance has shifted.Politicsread more
Jefferies told investors to buy select biotech names during this pre-election plunge due to attractive valuations and solid fundamentals.
"Though biotech volatility will likely continue into the election, at near-historic low multiples and with HC policy concerns valid but likely overstated, we see buying opp'ties," analyst Brian Abrahams wrote in a note to clients Tuesday.
"Biotech multiple [is] even more discounted vs. S&P since our last check — history suggests additional downside may be limited."
The iShares NASDAQ Biotechnology ETF is down 21.5 percent this year and has fallen 8 percent for the month as of Monday's close.
Abrahams said Donald Trump's recent troubles are raising concerns about a Democratic congressional sweep, which along with a Hillary Clinton victory could mean "more draconian drug-pricing changes." However, he cited how the average valuation of the four largest biotech companies (Amgen, Biogen, Celgene and Gilead) at 12 times earnings versus the 16.6 times earnings is already discounting the downside political risk.
Here are four buy-rated biotech stocks Jefferies recommends to take advantage of the call.